14.10.2015 • NewsDede WillamsSolvayHigh

Solvay Buys EPIC Polymers’ LFT Technology

Belgian chemical producer Solvay has acquired the long-fiber thermoplastics (LFT) technology of Germany’s EPIC Polymers to complement its offering of high performance light-weighting materials for the automotive industry. The privately owned Kaiserslautern-based firm is a leading supplier of high strength thermoplastics, tribologically optimized thermoplastics and conductive thermoplastics. Its new technology enables the reinforcement of high performance thermoplastic polymers with long glass fibers to make semi-structural parts replacing metal components in automobile exteriors.

Solvay said the sophisticated materials, in demand from automakers aiming to reduce fuel consumption, offer superior mechanical and thermal properties, coupled with high impact resistance, strength and stiffness at elevated temperatures. In addition to PEEK and PAEK polymers, the company will use the LFT technology in its Amodel PPA and Ryton PPS portfolio of products as well as in its Technyl range of PA 6.6.

Solvay Specialty Polymers already manufactures products that can replace metal in such demanding automotive under-the-hood components as hot air ducts, powertrains, engine control units, oil and water modules and conduits. These will be complemented in future by the LFT-based products for exterior applications.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.